Saebo

Leaders in Home Stroke Recovery

Saebo

Leaders in Home Stroke Recovery

Charlotte, NC
Health Tech
Consumer Products
Saebo’s award-winning rehabilitation products offer stroke survivors a second chance to overcome paralysis and regain quality-of-life. Designed specifically for ease-of-use and affordability, Saebo’s products are targeted to unlock the vast untapped market for in-home neurorehabilitation.

$217,331

raised
327
Investors
$11M
Valuation
$0.50
Price per Share
$248.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
Reg CF
Offering

$217,331

raised
327
Investors
$11M
Valuation
$0.50
Price per Share
$248.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
Reg CF
Offering

Rewards

Get rewarded for investing more into Saebo:

$248+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus. For details on the bonus, please see the Offering Summary section below
$500+
Investment
Supporter Level
Supporters will receive a $25 gift card for the products or swag of your choice at saebo.com. You’ll also receive a personalized coupon code to save 20% on any product of your choice.*
$1,000+
Investment
Bronze Investor Level
Bronze Investors will receive a $50 gift card for the products or swag of your choice at saebo.com. You’ll also receive a coupon code to save 20% on your entire next order.*
$2,500+
Investment
Silver Investor Level
Silver Investors will receive a $100 gift card for the products or swag of your choice at saebo.com. You’ll also receive a personalized coupon code to save 20% on all of your orders for an entire year.*
$5,000+
Investment
Gold Investor Level
Gold Investors will receive 10% Bonus Shares plus all of the Silver Level perks. In addition, Saebo will donate, in your name, $500 worth of products to patients in need.
$10,000+
Investment
Platinum Investor Level
Platinum Investors will receive 15% Bonus Shares plus all of the Silver Level perks. In addition, Saebo will donate, in your name, $1,000 worth of products to patients in need.

Reasons to Invest

Stroke is the #1 cause of long-term disability with a market size that is projected to double between 2010 and 2050.
As healthcare costs skyrocket, Saebo’s affordable home-based rehabilitation products improve patient recoveries while lowering the short- and long-term costs of care.
A proven track record with 17 patents awarded, a network spanning six continents and over 40 countries, and $44 million in net revenue to date.

Leaving no patient behind

Saebo is dedicated to bringing accessible, affordable, mobility solutions to all. Committed to “leaving no patient behind” Saebo sets out to create products that could benefit every patient. Saebo’s revolutionary product offering is based on the latest advances in rehabilitation research. From the SaeboFlex to the SaeboMAS, Saebo provides innovative and affordable rehabilitation products.

Saebo has grown into a leading global provider of rehabilitative products created through unrelenting leadership and a strong network of clinicians around the world. As we help over 600,000 clients regain function, we aim to make our newest products more accessible than ever.

The Problem


Stroke rehabilitation equipment is overpriced, ineffective, or too complicated for home use

Every 2.1 seconds, someone in the world suffers a stroke.  For those who are lucky enough to survive, overcoming paralysis can take months or even years of intense therapy.  


Too often, patients are treated in facilities that do not offer the latest advances in stroke rehabilitation technology. Then, they are often sent home with no effective home program and without the tools and resources they need to recover. Most at home stroke rehabilitation technology is overpriced, ineffective, or too complicated for home use.

All along the way, doctors routinely misinform stroke patients about the potential for additional recovery. Many patients are told that they have reached a recovery “plateau” and additional progress is no longer possible.

Without help, patients experience worsening paralysis, decreased range-of-motion, increased pain and depression, and a deteriorating quality-of-life. 


Making matters worse, even in developed countries like the U.S., insurance rarely covers the cost of long-term therapy or innovative rehabilitation products. 

The latest research demonstrates that it doesn’t have to be this way. Today, we now know that recovery can continue for many years, even decades, but only if patients get the help they need. 

The Solution


Providing effective and affordable rehabilitation products delivered directly to the patient’s home

Saebo creates effective, safe, and affordable products allowing every patient to maximize their neurological recovery, from the clinic to the home.

  • Each of our exclusive, easy-to-use products is designed and vetted by experienced, practicing clinicians. 

  • Our products are backed by years of clinical research and designed for simple use at home. 

  • Our FDA approved and non-invasive devices are affordable, even to those without insurance coverage. 

Our portfolio of products help stroke patients overcome a variety of impairments and maximize their recovery.

We have a product or service for every patient looking to improve their recovery at home.

And, because our products are guaranteed to be effective, affordable, and easy-to-use, patients can order any product on our website and enjoy a 30-Day Money-Back Guarantee.  We also provide a free evaluation, expert advice, and follow-up clinical support with each order.

gif

Our Traction


Saebo is a trusted brand with global reach

Our lifetime net revenue is at over $44 million and we’ve seen tremendous growth to-date across our B2B and B2C sectors:

  • A distributor network spanning 6 continents and over 40 countries

  • 17 Patents: our innovative product designs have been awarded 17 different patents by the US Patent Office

  • FDA clearance: our products has already satisfied FDA pre-marketing requirements or are regulated as class I devices, which are exempt from premarket requirements

  • Global adoption: Our products have been used by an estimated 800,000 patients in more than 4,000 hospitals around the world. 

Additionally, our products are recommended by the 10 top rehabilitation hospitals in the US (as ranked by US News and World Report). Our products and treatment approaches have now been featured in 20 different medical textbooks and publications, authored by the top neurologists and professors around the world. Saebo products and programs are featured in numerous university curriculums around the world.


Our very first product, the SaeboFlex, was recently put on permanent display at the London Science Museum alongside other breakthrough medical technologies such as penicillin and the first MRI.

The Business Model


A multi-channel distribution system, secured with high lifetime value

With over $44 million in net revenue to date, Saebo has a well-established multi-channel business model.


We sell products directly to the end-user through our D2C e-commerce platform. This platform leverages clinical expertise, producing educational content that generates over 250,000 website visits per month. This has paved the way for our significant digital footprint.

Another primary revenue stream is our B2B channel. We sell products directly to hospitals and treatment centers for use in the care of their patients. 


We also sell our products through various domestic and international healthcare providers and medical product distributors. This hybrid approach leverages a wide network of international distributors, who can then leverage their insurance networks and/or provider networks to navigate local compliance and logistics issues.

We have seen steady growth to-date across all of these channels:

  • 90% compound annual growth rate (CAGR) for products sold to US patients through our ecommerce platform since 2017.

  • 27% compound annual growth rate (CAGR) for direct-to-patient unit product sales between 2013 and 2018.

  • 10% compound annual growth rate (CAGR) for equipment sold to hospitals between 2013 and 2018.

And our multi-channel approach is now delivering scalable, capital-efficient growth opportunities based on falling customer acquisition costs and increasing customer lifetime values. Our current cost-per-acquisition is around $45 and our estimated lifetime value is about $300 per customer and rising.

The Market


Stroke is the #1 cause of long-term disability worldwide

Saebo is a well-established leader in the neurorehabilitation market for a significant population of stroke survivors:

  • Globally, there are over 15 million stroke survivors (source).

  • The U.S. alone is home to over 6.4 million stroke survivors with another 800,000 new survivors every year (source).

  • Between 2010 and 2050 the number of strokes in the U.S. is projected to double (source).

  • By 2030, almost 4% of US adults will have had a stroke (source).

  • Roughly 70% of stroke survivors are 65 or older; one of the fastest-growing demographics in the developed world (source).

  • Stroke is the number one cause of long-term adult disability worldwide (source).

  • The total direct annual stroke-related medical costs are projected to increase from $71 billion in 2012 to $183 billion by 2030 (source).

Consistent, long-term growth in the worldwide market for stroke rehabilitation products will be driven by a number of factors including:


  • Increasing stroke incidence levels due to changing demographics and lifestyles (as people live longer, they are more likely to have a stroke at some point in their lives).

  • Increasing stroke survival rates due to advances in acute medical care (growing number of survivors means more require post-stroke rehabilitation).

  • Increasing demand for new technologies due to advances in neuroscience (new evidence on cortical plasticity is demonstrating that old approaches to treatment are no longer adequate)

And finally, with COVID-19, we have seen an increased incidence of stroke. Particularly with pandemic restrictions, there is an increased urgency and demand for effective in-home therapy.

What we do


Improving stroke rehab: Reimagining what’s possible.

From hospital to home, our products and services support patients each step of the way.  Our patient-targeted solutions are designed to meet three simple criteria: 


  1. Proven Efficacy: every product we sell is based on treatment principles backed by science and years of clinical research

  2. Affordability: we focus on making every product we sell as affordable as possible; in fact, we even have several products and services that we offer for free!

  3. Ease-of-use: our products are vetted by clinicians with years of hands-on experience helping patients in real-world settings 

We also devote many of our resources to educating patients and clinicians around the world about the latest advancements in treatment and how our products incorporate those treatment paradigms.



Saebo Academy is approved by the American Occupational Therapy Association to provide accredited continuing education courses to clinicians. To date, more than 20,000 therapists have participated in our educational programs worldwide.

Our technology and ever-expanding product base continue to grow, with 17 existing patents, demonstrating our unique and innovative technologies.


Saebo has been a worldwide leader in stroke rehabilitation since 2004 and continues to lead the way for patient recovery-focused solutions.

The Vision


A Helping Hand For Every Patient

At Saebo, we believe every patient deserves a helping hand. That means empowering patients with the education, tools, and financial assistance they need to take control of their own recovery.

Today, Saebo is considered by many to be the foremost leader in stroke rehabilitation. Tomorrow, we look forward to bringing our expertise to an ever-expanding range of neurological conditions and impairments.

The stroke survivor population is only the beginning. We also help treat veterans with traumatic brain injuries at VA centers across the country. Millions suffering from Multiple Sclerosis, neuropathy, and other neurological disorders could benefit from our technology.

OUR LEADERSHIP


Decades of Diverse Expertise

With a combined 112 years of clinical experience and 49 years of management experience, the Saebo team is made up of exceptional leaders in business and medicine, poised to change the lives of patients around the world. 

Why Invest


We’ve helped about 1 million stroke patients worldwide. 79 million to go.

To continue to provide life-changing solutions for those suffering from impaired mobility and function, Saebo aims to expand global partnerships and provide directly accessible devices for every patient who needs them.

We hope to follow our momentum with funding from StartEngine for new product development, lower-cost product sourcing, a sophisticated DTP digital marketing platform, and additional domestic and international distribution channels and partners. We hope you will join the charge to provide innovative, affordable, and positively impactful solutions so that no patient is ever left behind.

gif

In the Press

Sioux City Journal: Devices help stroke patients regain hand, arm functionality
January 1, 2017

SaeboFlex supports Bradley Collins' wrist, allowing him to extend his left thumb and fingers in order to grasp and release objects.

The Telegraph: Long Blondes guitarist uses 'bionic hand' after stroke
January 1, 2017

The 27-year-old guitarist in popular indie band The Long Blondes hopes to play again despite suffering a stroke, thanks to cutting-edge medical technology.

BusinessWire: Hocoma and Saebo Partner to Deliver Compact, Affordable Rehabilitation Solution for Upper Extremities
January 1, 2017

Together, the SaeboMas Mini and the ArmeoSenso deliver an easy-to-use, compact solution at an affordable price.

PR Newsire/Cision: SaeboFlex, Revolutionary Neurological Hand Exoskeleton, on Permanent Public Display at London Science Museum

Saebo's flagship product, SaeboFlex, included in the newly created Medicine Wellcome Galleries revealing break-through medical treatment innovations spanning the last 500 years.

Petosky News Review: Cutting-edge equipment changes life of local stroke victim

Michael Seiler using the SaeboFlex during a rehabilitation session. After suffering a stroke in 2011, Seiler has put in years of hard work and continues to make progress with the Saebo equipment.

TriCity News: A helping hand needed for stroke victims at ERH

Hospital foundation raising funds for stroke rehabilitation equipment

PR Newsire/Cision: Saebo Announces FDA Clearance of SaeboVR - World's First Virtual ADL Rehabilitation System

Leader in unique, affordable technologies for individuals suffering from impaired mobility and function releases a virtual ADL system to maximize therapy outcomes.

Offering Summary


Company

:

SAEBO, Inc.

Corporate Address

:

2459 Wilkinson Blvd. Ste 120-B, Charlotte, NC 28208

Offering Minimum

:

$10,000.00

Offering Maximum

:

$1,069,999.00

Minimum Investment Amount

(per investor)

:

$248.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

20,000

Maximum Number of Shares Offered

:

2,139,998

Price per Share

:

$0.50

Pre-Money Valuation

:

$10,964,387.50











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Votings Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the President of the Company (the “President”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the President determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the President for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Time-Based:

Friends and Family Early Birds

Invest within the first 48 hours and receive an additional 20% bonus shares.

Super Early Bird Bonus

Invest within the first week and receive an additional 15% bonus shares.

Early Bird Bonus

Invest within the first two weeks and receive an additional 10% bonus shares.

Amount-Based:

$500+

Supporter Level

Supporters will receive a $25 gift card for the products or swag of your choice at saebo.com. You’ll also receive a personalized coupon code to save 20% on any product of your choice.*

$1,000+

Bronze Investor Level

Bronze Investors will receive a $50 gift card for the products or swag of your choice at saebo.com. You’ll also receive a coupon code to save 20% on your entire next order.*

$2,500+

Silver Investor Level

Silver Investors will receive a $100 gift card for the products or swag of your choice at saebo.com. You’ll also receive a personalized coupon code to save 20% on all of your orders for an entire year.*

$5,000+

Gold Investor Level

Gold Investors will receive 10% Bonus Shares plus all of the Silver Level perks. In addition, Saebo will donate, in your name, $500 worth of products to patients in need.

$10,000+

Platinum Investor Level

Platinum Investors will receive 15% Bonus Shares plus all of the Silver Level perks. In addition, Saebo will donate, in your name, $1,000 worth of products to patients in need.

*Excludes hospital-based treatment equipment (e.g., items priced over $5,000).

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Saebo, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $0.50 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $50. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

We will not incur any irregular use of proceeds.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$1,371,954.00 USD
$1,382,393.00 USD
Cash And Cash Equivalents
$25,660.00 USD
$90,733.00 USD
Accounts Receivable
$401,583.00 USD
$344,826.00 USD
Short Term Debt
$1,007,162.00 USD
$957,804.00 USD
Long Term Debt
$7,975,603.00 USD
$6,754,518.00 USD
Revenues And Sales
$4,444,270.00 USD
$4,470,674.00 USD
Costs Of Goods Sold
$1,783,145.00 USD
$1,801,561.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$1,195,857.00 USD
-$992,477.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

"I believe in Saebo" - Occupational Therapist Testimonial

8 days ago

Kim Hook is an Occupational Therapist who has used Saebo’s products in her practice for ten years. Learn why she is such a fan of Saebo’s products and why she continues to believe in the company.



Disclaimer: "This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success.”

Saebo reaches $200,000 raised milestone!

11 days ago

We asked people why they invested in Saebo! Here is what they had to say...

17 days ago

Notice of Funds Disbursement

about 1 month ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Saebo has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Saebo be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Saebo Q4 Update

about 1 month ago

Saebo’s preliminary 4th quarter sales results are in, and despite the COVID-19 pandemic, our North American Patient orders are up a remarkable 13% versus Q4 prior year. This despite the fact that many of the rehabilitation facilities that refer Patient Products to us were closed, or on a very limited schedule for much of the year.  Further, online orders of Patient Products through our shopping cart were up a whopping 53% for Q4 compared to Q4 2019, and up more than 50% for the full year, demonstrating the scalable nature of Saebo’s business model, and the continued strong demand for our Patient Products. 

 

Saebo further reports that International orders, including Saebo’s wholly-owned UK subsidiary, were up 8% in Q4 2020 vs. Q4 2019. This is significant because many of Saebo’s large international markets (e.g., Germany, Italy, Benelux, UK, etc.) were also seriously impacted by COVID-19 shutdowns and restrictions in 2020.

 

“These significant increases, especially under the circumstances, highlight the company’s successful pivot in the face of COVID-19 related challenges to the US healthcare systems,” said Saebo’s President, Henry Hoffman. “By promoting and delivering our products directly to patients for in-home use, we’ve been able to help our customers around the world continue their recoveries at home while increasing the most important and fastest-growing segments of our business."

Saebo makes the impossible possible!

about 2 months ago

Check out this 30-second video of a UK client making remarkable gains over the holiday break with the SaeboGlove and SaeboMAS. The patient started with little hand movement. Watch how these products transformed his recovery.

The cutting-edge SaeboGlove supports a survivor’s affected hand while they move throughout their day. The SaeboGlove assists the patient with normal hand activities like grasping household items and rebuilds muscular strength in the process. The proprietary tension system extends the fingers and thumb after grasping. The SaeboGlove is based on the latest advances in neurorehabilitation research about the brain’s ability to “reprogram” itself through mass practice, task-oriented arm training. 

The SaeboMAS, a zero-gravity arm support system, takes the weight off the shoulder and allows the arm to achieve the range of motion necessary for standard tasks and exercises. This, in turn, strengthens the muscles around the arm that would have otherwise gone unused. The SaeboMAS can assist with performing the prescribed repetitive motions that fight against joint pain, muscle spasticity, and weakness.

Thank you for a fantastic first week!

about 2 months ago

Thank you to our supporters! We reached our minimum raise in just 12 hours and now have over 130 new investors in Saebo! Here at Saebo, we are dedicated to bringing accessible, affordable, mobility solutions to all. We stay committed to “leaving no patient behind” and set out to create products that every patient can benefit from. If you have any questions about Saebo or our campaign, please feel free to leave us a comment below. Thank you!


Join Our First Stroke Survivor Investor!

about 2 months ago

Congratulations to Jeffrey Neal Isaac, Ph.D., our first Stroke Survivor to invest in Saebo. We want to thank all of our early investors and followers so far. Our vision is to help every patient, and there are about 79 million stroke survivors out there who could benefit from our solutions, just like our friend Jeffery did!

Disclaimer: "This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success.”

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}